Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects
Open Access
- 1 October 2010
- journal article
- research article
- Published by Elsevier BV in The American Journal of Clinical Nutrition
- Vol. 92 (4), 810-817
- https://doi.org/10.3945/ajcn.2010.29663
Abstract
Background: Peripheral infusion of glucagon-like peptide 1 (GLP-1) or peptide YY 3-36 (PYY3-36) reduces food intake in healthy, obese, and diabetic subjects. In vivo, both peptides are cosecreted from intestinal L cells; GLP-1 is subject to rapid breakdown by dipeptidyl peptidase IV, and together with PYY3-36 it is likely to be degraded in the liver before entering the systemic circulation. The largest concentrations are observed in the splanchnic blood rather than in the systemic circulation.Keywords
This publication has 29 references indexed in Scilit:
- Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male SubjectsClinical Pharmacology & Therapeutics, 2009
- Global burden of obesity in 2005 and projections to 2030International Journal of Obesity, 2008
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- Effect of Peptide YY3–36 on Food Intake in HumansGastroenterology, 2005
- Central nervous system control of food intakeNature, 2000
- Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studiesInternational Journal of Obesity, 2000
- Glucagon-like peptide-1: a potent regulator of food intake in humansGut, 1999
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.JCI Insight, 1998
- Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pigAmerican Journal of Physiology-Endocrinology and Metabolism, 1996
- Carbohydrates for Exercise: Dietary Demands for Optimal PerformanceInternational Journal of Sports Medicine, 1988